T. Rowe Price Associates
KLDO

T. Rowe Price Associates’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

T. Rowe Price Associates’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,356
Closed -$144K – 3013
2021
Q2 		$144K Sell
19,356
-3,571
-16% -$25.3K ﹤0.01% 2788
2021
Q1 		$186K Buy
22,927
+11,710
+104% +$128K ﹤0.01% 2708
2020
Q4 		$102K Buy
+11,217
New +$92K ﹤0.01% 2624

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's KLDO Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2021, closing a stake of 19,356 shares — an estimated $144K sold.

T. Rowe Price Associates first reported a position in KLDO in Q4 2020 and held it in 3 quarters. The position peaked at $186K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q3 2021.

  • T. Rowe Price Associates reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 19,356 Kaleido Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $144K.
  • T. Rowe Price Associates first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • T. Rowe Price Associates's Kaleido Biosciences, Inc. Common Stock position peaked at $186K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.